苏州瑞博生命科学（瑞博生物-B）近日宣布，已就6项针对代谢功能障碍相关脂肪性肝炎（MASH）治疗的临床前阶段小干扰RNA（siRNA）研发项目达成授权许可协议。该交易标志着公司在核酸药物研发领域，特别是在代谢性疾病治疗方向的战略布局取得重要进展。
苏州瑞博生命科学（瑞博生物-B）近日宣布，已就6项针对代谢功能障碍相关脂肪性肝炎（MASH）治疗的临床前阶段小干扰RNA（siRNA）研发项目达成授权许可协议。该交易标志着公司在核酸药物研发领域，特别是在代谢性疾病治疗方向的战略布局取得重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.